Agios Pharmaceuticals
AGIO
217 hedge funds and large institutions have $4.54B invested in Agios Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 83 increasing their positions, 61 reducing their positions, and 17 closing their positions.
118% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 17
42% more call options, than puts
Call options by funds: $46.9M | Put options by funds: $33M
36% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 61
10% more funds holding
Funds holding: 198 → 217 (+19)
1% more capital invested
Capital invested by funds: $4.49B → $4.54B (+$51.4M)
1.33% less ownership
Funds ownership: 95.79% → 94.46% (-1.3%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
+$40.6M |
| 2 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$34M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$29.2M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$14.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
-$29.4M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$24.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$21.9M |
| 4 |
PA
Perceptive Advisors
New York
|
-$20.4M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$15.6M |
AGIO Hedge Fund Activity: Q2 2018 in Review
217 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q2 2018, worth a combined $4.54B — up 1.1% from $4.49B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new AGIO positions and 17 closed out — a net gain of 20 holders — while 83 added to existing stakes and 61 trimmed.
The largest buyer was Polar Capital, opening a new position worth an estimated $40.6M. The largest seller was BB Biotech, cutting an estimated $29.4M.
- 217 institutional investors held Agios Pharmaceuticals (AGIO) as of Q2 2018, up from 198 in Q1 2018.
- Funds reported $4.54B of Agios Pharmaceuticals stock for Q2 2018, up 1.1% quarter-over-quarter.
- 37 funds opened new Agios Pharmaceuticals positions in Q2 2018 and 17 closed out, a net change of +20 holders.
- The largest Agios Pharmaceuticals buyer in Q2 2018 was Polar Capital, an estimated $40.6M added.
- The largest Agios Pharmaceuticals seller in Q2 2018 was BB Biotech, an estimated $29.4M sold.
Based on aggregated 13F filings for Q2 2018.